Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306112 | 1.00 | TSHR (0.52) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL498588 | 1.00 | TSHR (0.52) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL893216 | 0.83 | TSHR (0.52) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL6283476 | 0.82 | TSHR (0.65) | TSHRTAAR1CYP2D6LMNADPP4 | |
| SCHEMBL9750479 | 0.81 | TSHR (0.50) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL3280292 | 0.79 | ADRA2A (0.54) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| SCHEMBL4778223 | 0.79 | LMNA (0.48) | TSHRADRA2AADRA2CCYP2D6LMNA | |
| SCHEMBL11887151 | 0.79 | ADRA2A (0.54) | TSHRTAAR1ADRA2AADRA2CCYP2D6 | |
| Acetone SCHEMBL28777513 | 0.79 | CYP2D6 (0.43) | TSHRCYP2D6LMNAALDH1A1 | |
| SCHEMBL2240790 | 0.78 | TSHR (0.52) | TSHRTAAR1ADRA2AADRA2CCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3808740-A1 | ORAL DOSAGE FORMS COMPRISING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | TerSera Therapeutics LLC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3176159-B1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2020-10-21 | — | — | EP | disclosed |
| EP-3318260-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2020-09-23 | — | — | EP | disclosed |
| EP-3318260-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2- TRIFLUORO-1-PHENYLETHOXY) PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2091940-B3 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2187887-B1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3176159-A1 | 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2017-06-07 | — | — | EP | disclosed |
| EP-2589600-B1 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2017-02-15 | — | — | EP | disclosed |
| CN-104045626-B | Compounds based on 4-phenyl-6-(2,2,2-trifluoro-1-phenyl ethoxy) pyrimidine and application method thereof | 莱西肯医药有限公司 | 2017-01-11 | — | — | CN | disclosed |
| EP-2318380-B1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20100240906-A1 | 1-PHENYL-1H-PYRAZOLE-BASED COMPOUNDS | TERSERA THERAPEUTICS LLC | 2010-09-23 | — | — | US | disclosed |
| EP-2187887-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | Lexicon Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| US-7709493-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | LEXICON PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090318705-A1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-24 | — | — | US | disclosed |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TERSERA THERAPEUTICS LLC | 2009-11-19 | — | — | US | disclosed |
| US-7553840-B2 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | LEXICON PHARMACEUTICALS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2009029499-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062540-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | LEXICON PHARMACEUTICALS, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20080262241-A1 | Methods of Preparing Imidazole-Based Compounds | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2008-10-23 | — | — | US | disclosed |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TERSERA THERAPEUTICS LLC | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318705-A1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | PAICS, TOP2B, CCNI | TSHR 4010/4885TAAR1 3215/4885ADRA2A 2107/4885 |
| US-20090286817-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester | TPH1, TPH2, PAH | TSHR 962/4885TAAR1 448/4885ADRA2A 126/4885 |
| US-20080262241-A1 | Methods of Preparing Imidazole-Based Compounds | PAICS, TOP2B, PPIP5K2 | TSHR 3848/4885TAAR1 2985/4885ADRA2A 2026/4885 |
| US-20080153852-A1 | Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders | TPH1, TPH2, MAOA | TSHR 1054/4885TAAR1 354/4885ADRA2A 172/4885 |
| US-20100240906-A1 | 1-PHENYL-1H-PYRAZOLE-BASED COMPOUNDS | CYP2E1, CYP1B1, CYP11B1 | TSHR 3722/4885TAAR1 3269/4885ADRA2A 1461/4885 |
| US-20090062540-A1 | METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS | DPYD, TYMP, NUDT1 | TSHR 3411/4885TAAR1 2998/4885ADRA2A 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.